• Home
  • The Science
  • Nu.Q® Pipeline
    • Nu.Q®
    • Nu.Q® NETs
    • Nu.Q® Vet
    • Nu.Q® Capture
    • Nu.Q® Discover
  • About Us
    • Our Values
    • Our Expert Team
    • Contact Us
  • Investors
  • Resources
    • News Room
    • Scientific
    • Investors
    • Veterinary Resources
  • Join Mailing List
Volition
  • Home
  • The Science
  • Nu.Q® Pipeline
    • Nu.Q®
    • Nu.Q® NETs
    • Nu.Q® Vet
    • Nu.Q® Capture
    • Nu.Q® Discover
Volition
  • About Us
    • Our Values
    • Our Expert Team
    • Contact Us
  • Investors
  • Resources
    • News Room
      • Press Releases
      • Video Gallery
      • Media Toolkit
      • Downloads
    • Scientific
      • Clinical Papers & Posters
      • Presentations
      • Video Gallery
    • Investors
      • Presentations
      • Video Gallery
    • Veterinary Resources
  • Join Mailing List

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • Shareholders Letters
    • IR Calendar
    • Presentations
    • Email Alerts
  • Company Info
    • Overview
    • Executive Team
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • Shareholders Letters
  • IR Calendar
  • Presentations
  • Email Alerts
Jul 27, 2015 8:00am EDT

VolitionRx Engages Specialty Clinical Research Organization to Support Initial Entry of its NuQ(R) Colorectal Cancer Tests via U.S. CLIA Labs

Jul 08, 2015 8:00am EDT

VolitionRx CSO Dr. Jake Micallef to Present Scientific Webinar

Jul 06, 2015 8:18am EDT

VolitionRx Expands Scientific Advisory Board

Jun 23, 2015 8:00am EDT

VolitionRx Partners with Two Market Access Consulting Agencies to Support Market Access of NuQ(R) Colorectal Cancer Tests in Europe

May 19, 2015 8:00am EDT

VolitionRx to Present at Two Upcoming Investor Conferences

May 18, 2015 8:00am EDT

VolitionRx CEO Cameron Reynolds to Present Informational Webinar

May 12, 2015 7:50am EDT

VolitionRx Announces First Quarter 2015 Financial Results and Business Update

May 08, 2015 8:00am EDT

VolitionRx Accelerates Clinical Trial with University Hospital Bonn, Germany Evaluating NuQ® Assays in Most Prevalent Cancers

May 06, 2015 8:00am EDT

VolitionRx Schedules First Quarter 2015 Earnings Conference Call and Business Update for Tuesday, May 12, 2015 at 8:30 a.m. ET

Apr 21, 2015 8:00am EDT

VolitionRx Initiates Study with Hvidovre Hospital, Denmark, Specifically to Target NuQ(R) Biomarker Panel for Colorectal Polyps

  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 20
  • Page 21
  • Page 22
  • Page 23
  • Page 24
  • Page 25
  • Page 26
  • Page 27
  • Page 28
  • Page 29
  • …
  • Page 31
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
  • Contact Us
  • Downloads
  • Privacy Policy
  • Disclaimer
  • Manage Cookie Preferences
Sign up to  email alerts
linkedin facebook twitter
artboard

The European Regional Development Fund and Wallonia are investing in your future

http://europe.wallonie.be
artboard
artboard

The European Regional Development Fund and Wallonia are investing in your future

http://europe.wallonie.be
artboard

MENAC - Epigenetic Modifications of Nucleosomes Associated with Cancer

Thanks to a grant of 1.990.798€ from the European Regional Development Fund and Walloon Government, we’re taking part in the MENAC project which aims to develop innovative non-invasive tests for the early detection of different types of cancer. We’re working in partnership with Synabs to create monoclonal antibodies and develop new diagnostic and theragnostic immunoassays.